Navigation Links
Palatin Technologies and King Pharmaceuticals Announce Plan To,Present Results of Bremelanotide Phase 2b Studies in Men With,Erectile Dysfunction

t ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia, and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's lead product candidate, bremelanotide, is currently in Phase 2 clinical trials for both male and female sexual dysfunction. Palatin's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, Palatin has entered into collaborations with AstraZeneca, King Pharmaceuticals, and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

Forward-looking Statements

<
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... 26, 2014 (HealthDay News) -- Most babies and young ... the U.S. Food and Drug Administration says. Over-the-counter ... to children younger than 2 because they could cause ... American adults average about three colds a year, ... a cold, parents might want to give them pain ...
(Date:11/27/2014)... 27, 2014 In order to enable people ... Fla., designed an easy way to avoid touching a toilet ... then created a prototype of the patent-pending Toilet Tamer, a ... toilet seat and/or lid in a more sanitary manner. It ... of germs. Overall, it promotes good hygiene and peace of ...
(Date:11/27/2014)... 2014 Now that Thanksgiving is finally ... launched, Emassagechair.com has announced its eagerly awaited, ... , Negotiating on behalf of their customers, and ... brands, Emassagechair.com has generated significant buzz in the industry ... discounts yet. , Shoppers are excited for significant savings ...
(Date:11/27/2014)... VogueQueen.com is making every effort to ... the world. As the premier online supplier of elegant ... to release a huge selection of sexy prom dresses ... is also providing many beautiful styles in its product ... at discounted prices. , “VogueQueen.com hopes to provide a ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2
... mid-October, ahead of vaccine delivery , THURSDAY, Sept. 10 (HealthDay ... flu outbreak is expected in October, but a planned vaccine ... suggests. , The first batch of the new H1N1 vaccine, ... according to the U.S. Centers for Disease Control and Prevention. ...
... Boston Scientific Corporation (NYSE: BSX ) is scheduled to ... , Ray Elliott, President and Chief Executive Officer ... participate in a 35-minute discussion about the Company on Tuesday, September ... , A live webcast of this discussion will be ...
... ... reconstruction, quicker recovery and more natural knee motion post-surgery , ... Evanston, Illinois (Vocus) -- NorthShore University ... use a new and innovative robotic technology for minimally-invasive partial knee replacement ...
... , , WOODCLIFF ... today announced that it has received final approval from the U.S. ... nateglinide tablets. Nateglinide is a generic version of Novartis, Starlix(R). ... to IMS Health data. Par will begin shipping the 60mg ...
... , , WARSAW, Ind., ... leading independent provider of products to the global orthopedic device industry and ... Executive Officer, and Fred L. Hite, Senior Vice President and Chief Financial ... at the Grand Hyatt Grand Central Hotel in New York City on ...
... , , NEW DELHI, Sept. 10 ... in India -- today announced an inspiring list of speakers for the ... theme of TEDIndia is "The Future Beckons." , , ... from diverse disciplines. Doctor and researcher Hans Rosling will share ...
Cached Medicine News:Health News:Swine Flu Shots May Come Too Late to Stem Fall Outbreak: Study 2Health News:Swine Flu Shots May Come Too Late to Stem Fall Outbreak: Study 3Health News:Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference 2Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 2Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 3Health News:NorthShore University HealthSystem First in Illinois to Perform Remarkable Robotic Arm Guided Partial Knee Replacement Surgery 4Health News:Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R) 2Health News:Symmetry Medical to Present at UBS Global Life Sciences Conference 2Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 2Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 3Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 4Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 5Health News:TEDIndia Announces List of Inspiring Speakers from Across the Globe 6
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Medicine Products: